Original Research
Published on 12 Oct 2021
Dapagliflozin, as Add-on Therapy in Type 2 Diabetes Patients, Is Associated With a Reduction in Albuminuria and Serum Transaminase Levels
in Diabetes Therapies
Frontiers in Clinical Diabetes and Healthcare
doi 10.3389/fcdhc.2021.733693
- 2,049 views
- 1 citation